Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kristina S. Yu"'
Autor:
Dahlia Sano, Nicholas Liu, Scott Knowles, Joanna P. MacEwan, Shu Wang, Jenifer Wogen, Kristina S. Yu, Seung Tae Lee
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2598-2609 (2024)
Brentuximab vedotin (BV) monotherapy (BV-M) and combination (BV-C) therapies are safe and effective for classical Hodgkin lymphoma (cHL) and CD30-expressing peripheral T-cell lymphomas (PTCLs). Although the sample sizes have been small (12–29 patie
Externí odkaz:
https://doaj.org/article/e9059c3f9a7c45858d95d53c40d18ec8
Autor:
Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle Fanale, John M. Burke
Publikováno v:
Leukemia & Lymphoma. :1-9
Publikováno v:
Advances in Therapy. 40:2326-2338
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 29:314-323
Autor:
Mayur Narkhede, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Allison Winter
Publikováno v:
Blood. 140:10798-10800
Autor:
John M Burke, Nicholas Liu, Kristina S Yu, Michelle A Fanale, Andy Surinach, Carlos Flores, Julie Lisano, Tycel Phillips
Publikováno v:
The Oncologist.
Background Since Food and Drug Administration approval of brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (A + CHP) as initial therapy for previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), t
Autor:
Susan K. Parsons, Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, Andrew M. Evens
Publikováno v:
JCO Oncology Practice.
PURPOSE We surveyed oncologists who treat classic Hodgkin lymphoma (cHL) as part of the CONNECT study to understand the treatment decision‐making process, including the impact of positron emission tomography/computed tomography (PET/CT) imaging. ME
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Autor:
Allison Winter, Nicholas Liu, Andy Surinach, Michelle A. Fanale, Kristina S. Yu, Mayur Narkhede
Publikováno v:
Blood. 140:8054-8055
Autor:
Vadim S Koshkin, Christine Boyiddle, Naomi Schwartz, Judy Yu, Kristina S. Yu, Ashley Kang, Lisa Bloudek, Qijun Fang, Johanna M. Schafer, Amanda F. Baker, Farzaneh H. Sayedian, Emilie Scherrer
Publikováno v:
Journal of Clinical Oncology. 41:556-556
556 Background: Recent clinical trials suggest an emerging role for HER2-targeted therapy in locally advanced and metastatic UC (LA/mUC). The prevalence of HER2 expression and gene amplification (encoded by ERBB2) in LA/mUC has not been well defined,